Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions

B. R. Blazar, C. J. Lees, P. J. Martin, R. J. Noelle, B. Kwon, William J Murphy, P. A. Taylor

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Delayed lymphocyte infusions (DLIs) are used to treat relapse occurring post bone marrow transplantation (BMT) and to increase the donor chimerism in recipients receiving nonmyeloablative conditioning. As compared with donor lymphocytes given early post-BMT, DLIs are associated with a reduced risk of graft-vs-host disease (GVHD). The mechanism(s) responsible for such resistance have remained incompletely defined. We now have observed that host T cells present 3 wk after lethal total body irradiation, at the time of DLI, contribute to DLI-GVHD resistance. The infusion of donor splenocytes on day 0, a time when host bone marrow (BM)-derived T cells are absent, results in greater expansion than later post-BMT when host and donor BM-derived T cells coexist. Selective depletion of host T cells with anti-Thy1 allelic mAb increased the GVHD risk of DLI, indicating that a Thy1+ host T cell regulated DLI-GVHD lethality. The conditions by which host T cells are required for optimal DLI resistance were determined. Recipients unable to express CD28 or 4-1BB were as susceptible to DLI-GVHD as anti-Thy1 allelic mAb-treated recipients, indicating that CD28 and 4-1BB are critical to DLI-GVHD resistance. Recipients deficient in both perforin and Fas ligand but not individually were highly susceptible to DLI-GVHD. Recipients that cannot produce IFN-γ were more susceptible to DLI-GVHD, whereas those deficient in IL-12 or p55 TNFRI were not. Collectively, these data indicate that host T cells, which are capable of generating antidonor CTL effector cells, are responsible for the impaired ability of DLI to induce GVHD. These same mechanisms may limit the efficacy of DLI in cancer therapy under some conditions.

Original languageEnglish (US)
Pages (from-to)4901-4909
Number of pages9
JournalJournal of Immunology
Volume165
Issue number9
StatePublished - Nov 1 2000
Externally publishedYes

Fingerprint

Graft vs Host Disease
Leukocytes
Lymphocytes
T-Lymphocytes
Bone Marrow Transplantation
Disease Resistance
Bone Marrow
Perforin
Chimerism
Fas Ligand Protein
Whole-Body Irradiation
Interleukin-12

ASJC Scopus subject areas

  • Immunology

Cite this

Blazar, B. R., Lees, C. J., Martin, P. J., Noelle, R. J., Kwon, B., Murphy, W. J., & Taylor, P. A. (2000). Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. Journal of Immunology, 165(9), 4901-4909.

Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. / Blazar, B. R.; Lees, C. J.; Martin, P. J.; Noelle, R. J.; Kwon, B.; Murphy, William J; Taylor, P. A.

In: Journal of Immunology, Vol. 165, No. 9, 01.11.2000, p. 4901-4909.

Research output: Contribution to journalArticle

Blazar, BR, Lees, CJ, Martin, PJ, Noelle, RJ, Kwon, B, Murphy, WJ & Taylor, PA 2000, 'Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions', Journal of Immunology, vol. 165, no. 9, pp. 4901-4909.
Blazar BR, Lees CJ, Martin PJ, Noelle RJ, Kwon B, Murphy WJ et al. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. Journal of Immunology. 2000 Nov 1;165(9):4901-4909.
Blazar, B. R. ; Lees, C. J. ; Martin, P. J. ; Noelle, R. J. ; Kwon, B. ; Murphy, William J ; Taylor, P. A. / Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. In: Journal of Immunology. 2000 ; Vol. 165, No. 9. pp. 4901-4909.
@article{ddc1802f82df4701b9dfe67affd9115b,
title = "Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions",
abstract = "Delayed lymphocyte infusions (DLIs) are used to treat relapse occurring post bone marrow transplantation (BMT) and to increase the donor chimerism in recipients receiving nonmyeloablative conditioning. As compared with donor lymphocytes given early post-BMT, DLIs are associated with a reduced risk of graft-vs-host disease (GVHD). The mechanism(s) responsible for such resistance have remained incompletely defined. We now have observed that host T cells present 3 wk after lethal total body irradiation, at the time of DLI, contribute to DLI-GVHD resistance. The infusion of donor splenocytes on day 0, a time when host bone marrow (BM)-derived T cells are absent, results in greater expansion than later post-BMT when host and donor BM-derived T cells coexist. Selective depletion of host T cells with anti-Thy1 allelic mAb increased the GVHD risk of DLI, indicating that a Thy1+ host T cell regulated DLI-GVHD lethality. The conditions by which host T cells are required for optimal DLI resistance were determined. Recipients unable to express CD28 or 4-1BB were as susceptible to DLI-GVHD as anti-Thy1 allelic mAb-treated recipients, indicating that CD28 and 4-1BB are critical to DLI-GVHD resistance. Recipients deficient in both perforin and Fas ligand but not individually were highly susceptible to DLI-GVHD. Recipients that cannot produce IFN-γ were more susceptible to DLI-GVHD, whereas those deficient in IL-12 or p55 TNFRI were not. Collectively, these data indicate that host T cells, which are capable of generating antidonor CTL effector cells, are responsible for the impaired ability of DLI to induce GVHD. These same mechanisms may limit the efficacy of DLI in cancer therapy under some conditions.",
author = "Blazar, {B. R.} and Lees, {C. J.} and Martin, {P. J.} and Noelle, {R. J.} and B. Kwon and Murphy, {William J} and Taylor, {P. A.}",
year = "2000",
month = "11",
day = "1",
language = "English (US)",
volume = "165",
pages = "4901--4909",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "9",

}

TY - JOUR

T1 - Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions

AU - Blazar, B. R.

AU - Lees, C. J.

AU - Martin, P. J.

AU - Noelle, R. J.

AU - Kwon, B.

AU - Murphy, William J

AU - Taylor, P. A.

PY - 2000/11/1

Y1 - 2000/11/1

N2 - Delayed lymphocyte infusions (DLIs) are used to treat relapse occurring post bone marrow transplantation (BMT) and to increase the donor chimerism in recipients receiving nonmyeloablative conditioning. As compared with donor lymphocytes given early post-BMT, DLIs are associated with a reduced risk of graft-vs-host disease (GVHD). The mechanism(s) responsible for such resistance have remained incompletely defined. We now have observed that host T cells present 3 wk after lethal total body irradiation, at the time of DLI, contribute to DLI-GVHD resistance. The infusion of donor splenocytes on day 0, a time when host bone marrow (BM)-derived T cells are absent, results in greater expansion than later post-BMT when host and donor BM-derived T cells coexist. Selective depletion of host T cells with anti-Thy1 allelic mAb increased the GVHD risk of DLI, indicating that a Thy1+ host T cell regulated DLI-GVHD lethality. The conditions by which host T cells are required for optimal DLI resistance were determined. Recipients unable to express CD28 or 4-1BB were as susceptible to DLI-GVHD as anti-Thy1 allelic mAb-treated recipients, indicating that CD28 and 4-1BB are critical to DLI-GVHD resistance. Recipients deficient in both perforin and Fas ligand but not individually were highly susceptible to DLI-GVHD. Recipients that cannot produce IFN-γ were more susceptible to DLI-GVHD, whereas those deficient in IL-12 or p55 TNFRI were not. Collectively, these data indicate that host T cells, which are capable of generating antidonor CTL effector cells, are responsible for the impaired ability of DLI to induce GVHD. These same mechanisms may limit the efficacy of DLI in cancer therapy under some conditions.

AB - Delayed lymphocyte infusions (DLIs) are used to treat relapse occurring post bone marrow transplantation (BMT) and to increase the donor chimerism in recipients receiving nonmyeloablative conditioning. As compared with donor lymphocytes given early post-BMT, DLIs are associated with a reduced risk of graft-vs-host disease (GVHD). The mechanism(s) responsible for such resistance have remained incompletely defined. We now have observed that host T cells present 3 wk after lethal total body irradiation, at the time of DLI, contribute to DLI-GVHD resistance. The infusion of donor splenocytes on day 0, a time when host bone marrow (BM)-derived T cells are absent, results in greater expansion than later post-BMT when host and donor BM-derived T cells coexist. Selective depletion of host T cells with anti-Thy1 allelic mAb increased the GVHD risk of DLI, indicating that a Thy1+ host T cell regulated DLI-GVHD lethality. The conditions by which host T cells are required for optimal DLI resistance were determined. Recipients unable to express CD28 or 4-1BB were as susceptible to DLI-GVHD as anti-Thy1 allelic mAb-treated recipients, indicating that CD28 and 4-1BB are critical to DLI-GVHD resistance. Recipients deficient in both perforin and Fas ligand but not individually were highly susceptible to DLI-GVHD. Recipients that cannot produce IFN-γ were more susceptible to DLI-GVHD, whereas those deficient in IL-12 or p55 TNFRI were not. Collectively, these data indicate that host T cells, which are capable of generating antidonor CTL effector cells, are responsible for the impaired ability of DLI to induce GVHD. These same mechanisms may limit the efficacy of DLI in cancer therapy under some conditions.

UR - http://www.scopus.com/inward/record.url?scp=0034327197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034327197&partnerID=8YFLogxK

M3 - Article

C2 - 11046015

AN - SCOPUS:0034327197

VL - 165

SP - 4901

EP - 4909

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 9

ER -